Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Lafutidine and Irsogladine in Healthy Volunteers
NCT02581696Phase 1Completed
- Sponsor
- Boryung
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lafutidine in peptic ulcer disease (PUD), sponsored by Boryung. Primary endpoint: Area under the plasma concentration versus time curve at 24 hours. Started Aug 2015; status: completed.
02
Drugs
lafutidine
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02581696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581696.